High hydrostatic pressure affects antigenic pool in tumor cells: Implication for dendritic cell-based cancer immunotherapy
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F17%3A10373793" target="_blank" >RIV/00216208:11130/17:10373793 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/17:10373793
Result on the web
<a href="https://doi.org/10.1016/j.imlet.2017.05.005" target="_blank" >https://doi.org/10.1016/j.imlet.2017.05.005</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.imlet.2017.05.005" target="_blank" >10.1016/j.imlet.2017.05.005</a>
Alternative languages
Result language
angličtina
Original language name
High hydrostatic pressure affects antigenic pool in tumor cells: Implication for dendritic cell-based cancer immunotherapy
Original language description
High hydrostatic pressure (HHP) can be used to generate dendritic cell (DC)-based active immunotherapy for prostate, lung and ovarian cancer. We showed here that HHP treatment of selected human cancer cell lines leads to a degradation of tumor antigens which depends on the magnitude of HHP applied and on the cancer cell line origin. Whereas prostate or ovarian cell lines displayed little protein antigen degradation with HHP treatment up to 300 MPa after 2 h, tumor antigens are hardly detected in lung cancer cell line after treatment with HHP 250 MPa at the same time. On the other hand, quick reduction of tumor antigen-coding mRNA was observed at HHP 200 MPa immediately after treatment in all cell lines tested. To optimize the DC -based active cellular therapy protocol for HHP-sensitive cell lines the immunogenicity of HHP-treated lung cancer cells at 150, 200 and 250 MPa was compared. Lung cancer cells treated with HHP 150 MPa display characteristics of immunogenic cell death, however cells are not efficiently phagocytosed by DC. Despite induction of the highest number of antigen-specific CD8(+) T cells, 150 MPa-treated lung cancer cells survive in high numbers. This excludes their use in DC vaccine manufacturing. HHP of 200 MPa treatment of lung cancer cells ensures the optimal ratio of efficient immunogenic killing and delivery of protein antigens in DC. These results represent an important pre-clinical data for generation of immunogenic killed lung cancer cells in ongoing NSCLC Phase I/II clinical trial using DC-based active cellular immunotherapy (DCVAC/LuCa).
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30102 - Immunology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Immunology Letters
ISSN
0165-2478
e-ISSN
—
Volume of the periodical
187
Issue of the periodical within the volume
July
Country of publishing house
NL - THE KINGDOM OF THE NETHERLANDS
Number of pages
8
Pages from-to
27-34
UT code for WoS article
000403633100005
EID of the result in the Scopus database
2-s2.0-85019120416